Please assess the completion status of the following clinical trial:

Trial Title: Changes in Health and Functional Status in Patients With Chronic Obstructive Pulmonary Disease During Therapy With Spiolto® Respimat® (AERIAL®)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Patients can be included if all of the following criteria are met:~* Written informed consent prior to participation~* Female and male patients ≥40 years of age~* Patients diagnosed with COPD and requiring a combination of two long-acting bronchodilators (LAMA + LABA) according to approved SmPC and GOLD COPD guideline recommendation 2017 (GOLD COPD groups B to D)~* Treatment with Spiolto® Respimat® acc. to SmPC at the discretion of the physician.~Exclusion Criteria:~* Patients with contraindications according to Spiolto® Respimat® SmPC~* Patients already on a LABA/LAMA combination (free and fixed dose) in the last 6 weeks before study entry~* Patients continuing LABA-ICS treatment should not be additionally treated with Spiolto® Respimat® in order to avoid a double dosing of long-acting beta-agonists~* Pregnancy and lactation~* Current participation in any clinical trial or any other non-interventional study of a drug or device.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- patients treated with Spiolto® Respimat® (Type: None): Patients with COPD

Based on this trial design, predict the completion outcome and termination type (if applicable).